Patents by Inventor James H. Adair
James H. Adair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210338705Abstract: Method of producing nanoparticle of drug and imaging agents are provided. The phosphorylated encapsulated drugs and imaging agents could be encapsulated at therapeutic levels, were encapsulated at higher amounts. The CPSNPs were more effective in treating cancer, in reducing cancer proliferation, arresting cancer cell growth than when not in the form of a CPSNP, and showed efficacious treatment of cancer cells at far lower dosage than free molecules. Calcium phosphosilicate and phosphate nanoparticles are disclosed and their method of use. The methods and nanoparticles are particularly efficacious where CPSNPs were used to encapsulate 5-FU metabolites such as FdUMP and gemcitabine metabolites.Type: ApplicationFiled: June 9, 2021Publication date: November 4, 2021Inventors: James H. Adair, Gail L. Matters, Welley S. Loc, Amra Tabakovic, Mark Kester, Sam Linton, Christopher McGovern, Xiaomeng Tang, Gary A. Clawson, Jill P. Smith, Tye Deering
-
ENCAPSULATION AND HIGH LOADING EFFICIENCY OF PHOSPHORYLATED DRUG AND IMAGING AGENTS IN NANOPARTICLES
Publication number: 20190255087Abstract: Method of producing nanoparticle of drug and imaging agents are provided. The phosphorylated encapsulated drugs and imaging agents could be encapsulated at therapeutic levels, were encapsulated at higher amounts. The CPSNPs were more effective in treating cancer, in reducing cancer proliferation, arresting cancer cell growth than when not in the form of a CPSNP, and showed efficacious treatment of cancer cells at far lower dosage than free molecules. Calcium phosphosilicate and phosphate nanoparticles are disclosed and their method of use. The methods and nanoparticles are particularly efficacious where CPSNPs were used to encapsulate 5-FU metabolites such as FdUMP and gemcitabine metabolites.Type: ApplicationFiled: April 12, 2019Publication date: August 22, 2019Inventors: James H. Adair, Gail L. Matters, Welley S. Loc, Amra Tabakovic, Mark Kester, Sam Linton, Christopher McGovern, Xiaomeng Tang, Gary A. Clawson, Jill P. Smith, Tye Deering -
Publication number: 20180064347Abstract: Systems comprising a combination of the handheld imaging system with a nanoparticle multimodal contrast agent are disclosed. The imaging system exploits the advantages of both near-infrared emission and the photoacoustic effect by employing calcium phosphosilicate nanocolloid that encapsulates NIR and CT/MRI contrast agents for enhanced deep tissue imaging as well as a portable NIR/PA system using a tunable pulsed laser, CCD imaging technology and acoustic transducer arrays. Methods for using the system, for example in rapid diagnosis of trauma such as that inflicted on a battlefield, are provided.Type: ApplicationFiled: September 8, 2017Publication date: March 8, 2018Inventors: JAMES H. ADAIR, SEAN D. KNECHT, J. ERIC BOYER, RICHARD L. TUTWILER, CONNOR CARR, XIAOMENG TANG, BERNADETTE M. ADAIR, THOMAS NEUBERGER, WELLEY S. LOC, ZACHARY R. WILCZYNSKI, CHRISTOPHER MCGOVERN, GAIL L. MATTERS, KEITH CHENG, MARK KESTER, LAWRENCE SINOWAY
-
Publication number: 20170274100Abstract: Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.Type: ApplicationFiled: October 2, 2015Publication date: September 28, 2017Inventors: James H. Adair, Erhan Altinoglu, Brian M. Barth, James M. Kaiser, Mark Kester, Gail L. Matters, Christopher McGovern, Thomas T. Morgan, Sriram S. Shanmugavelandy, Rahul Sharma, Jill P. Smith
-
ENCAPSULATION AND HIGH LOADING EFFICIENCY OF PHOSPHORYLATED DRUG AND IMAGING AGENTS IN NANOPARTICLES
Publication number: 20170209478Abstract: Method of producing nanoparticle of drug and imaging agents are provided. The phosphorylated encapsulated drugs and imaging agents could be encapsulated at therapeutic levels, were encapsulated at higher amounts. The CPSNPs were more effective in treating cancer, in reducing cancer proliferation, arresting cancer cell growth than when not in the form of a CPSNP, and showed efficacious treatment of cancer cells at far lower dosage than free molecules. Calcium phosphosilicate and phosphate nanoparticles are disclosed and their method of use. The methods and nanoparticles are particularly efficacious where CPSNPs were used to encapsulate 5-FU metabolites such as FdUMP and gemcitabine metabolites.Type: ApplicationFiled: January 20, 2017Publication date: July 27, 2017Inventors: James H. Adair, Gail Matters, Welley S. Loc, Amra Tabakovic, Mark Kester, Sam Linton, Christopher McGovern, Christopher Gigliotti, Xiaomeng Tang, Peter J. Butler, Gary A. Clawson, Jill P. Smith -
Publication number: 20160206633Abstract: Use of dhS1P and/or PhotoImmunoNanoTherapy as a therapeutic agent is described. Administration of therapeutically effective amounts of dhS1P decrease the number of Myeloid Derived Suppressor Cells and immune suppression in cancer patients. Administration of therapeutically effective amounts of dhS1P can be used as an adjuvant to conventional cancer therapies including immunotherapies. Therapeutic results can be achieved by directly administering dhS1P and/or by indirectly increasing the amount of dhS1P at the tumor site. The therapy permits the patient's immune system to recognize and eliminate cancer cells reducing tumor size and extending patient survival.Type: ApplicationFiled: January 15, 2016Publication date: July 21, 2016Inventors: Brian M. Barth, Mark Kester, James H. Adair, Todd E. Fox
-
Patent number: 9326953Abstract: A system and method for optimizing the systemic delivery of growth-arresting lipid-derived bioactive drugs or gene therapy agents to an animal or human in need of such agents utilizing nanoscale assembly systems, such as liposomes, resorbable and non-aggregating nanoparticle dispersions, metal or semiconductor nanoparticles, or polymeric materials such as dendrimers or hydrogels, each of which exhibit improved lipid solubility, cell permeability, an increased circulation half life and pharmacokinetic profile with improved tumor or vascular targeting.Type: GrantFiled: November 9, 2012Date of Patent: May 3, 2016Assignee: The Penn State Research FoundationInventors: Mark Kester, Thomas Stover, Tao Lowe, James H. Adair, Young Shin Kim
-
Patent number: 9149544Abstract: Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.Type: GrantFiled: November 8, 2010Date of Patent: October 6, 2015Assignee: THE PENN STATE RESEARCH FOUNDATIONInventors: Thomas T. Morgan, Brian M. Barth, James H. Adair, Rahul Sharma, Mark Kester, Sriram S. Shanmugavelandy, Jill P. Smith, Erhan I. Altinoglu, Gail L. Matters, James M. Kaiser, Christopher McGovern
-
Patent number: 9028863Abstract: A system and method for optimizing the systemic delivery of growth-arresting lipid-derived bioactive drugs or gene therapy agents to an animal or human in need of such agents utilizing nanoscale assembly systems, such as liposomes, resorbable and non-aggregating nanoparticle dispersions, metal or semiconductor nanoparticles, or polymeric materials such as dendrimers or hydrogels, each of which exhibit improved lipid solubility, cell permeability, an increased circulation half life and pharmacokinetic profile with improved tumor or vascular targeting.Type: GrantFiled: April 26, 2004Date of Patent: May 12, 2015Assignee: The Penn State Research FoundationInventors: Mark Kester, Thomas Stover, Tao Lowe, James H. Adair, Young Shin Kim
-
Publication number: 20140205669Abstract: Use of dhS1P and/or PhotoImmunoNanoTherapy as a therapeutic agent is described. Administration of therapeutically effective amounts of dhS1P decrease the number of Myeloid Derived Suppressor Cells and immune suppression in cancer patients. Administration of therapeutically effective amounts of dhS1P can be used as an adjuvant to conventional cancer therapies including immunotherapies. Therapeutic results can be achieved by directly administering dhS1P and/or by indirectly increasing the amount of dhS1P at the tumor site. The therapy permits the patient's immune system to recognize and eliminate cancer cells reducing tumor size and extending patient survival.Type: ApplicationFiled: November 26, 2013Publication date: July 24, 2014Applicant: THE PENN STATE RESEARCH FOUNDATIONInventors: Brian M. Barth, Mark Kester, James H. Adair, Todd E. Fox
-
Patent number: 8771741Abstract: Nano-encapsulated photosensitizers and their use in the treatment of tumors and/or imaging is described. Preferably, the photosensitizers are encapsulated in a calcium phosphate nanoparticle (CPNP). Encapsulating the PS in a CPNP increases the half-life of the PS, increases absorption of the PS into the target cell tissue, increases the photostability of the PS, increases the photoefficiency of the PS, increases in vivo retention of the PS, or combinations thereof, ultimately making it a highly efficacious agent for use in photodynamic therapy, imaging target tissues, vessels, or tumors, and/or detecting or locating tumors.Type: GrantFiled: January 22, 2010Date of Patent: July 8, 2014Assignee: The Penn State Research FoundationInventors: James H. Adair, Mark Kester, Erhan I. Altinoglu, Brian M. Barth, Timothy J. Russin, James M. D. Kaiser, Thomas T. Morgan, Karen L. Eklund
-
Publication number: 20140154325Abstract: Nano-encapsulated photosensitizers and their use in the treatment of tumors and/or imaging is described. Preferably, the photosensitizers are encapsulated in a calcium phosphate nanoparticle (CPNP). Encapsulating the PS in a CPNP increases the half-life of the PS, increases absorption of the PS into the target cell tissue, increases the photostability of the PS, increases the photoefficiency of the PS, increases in vivo retention of the PS, or combinations thereof, ultimately making it a highly efficacious agent for use in photodynamic therapy, imaging target tissues, vessels, or tumors, and/or detecting or locating tumors.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: THE PENN STATE RESEARCH FOUNDATIONInventors: James H. Adair, Mark Kester, Peter C. Eklund, Erhan I. Altinoglu, Brian M. Barth, Timothy J. Russin, James M.D. Kaiser, Thomas T. Morgan
-
Publication number: 20130295159Abstract: A system and method for optimizing the systemic delivery of growth-arresting lipid-derived bioactive drugs or gene therapy agents to an animal or human in need of such agents utilizing nanoscale assembly systems, such as liposomes, resorbable and non-aggregating nanoparticle dispersions, metal or semiconductor nanoparticles, or polymeric materials such as dendrimers or hydrogels, each of which exhibit improved lipid solubility, cell permeability, an increased circulation half life and pharmacokinetic profile with improved tumor or vascular targeting.Type: ApplicationFiled: November 9, 2012Publication date: November 7, 2013Inventors: Mark Kester, Thomas Stover, Tao Lowe, James H. Adair, Young Shin Kim
-
Patent number: 8530039Abstract: A polycrystalline mesoscale component, formed through a process including filing a mold cavity formed in a photoresist with a mold fill, is provided with an overall length L divided into multiple segments with a second segment extending from a first segment at a nonlinear angle. The first segment has a first segment height H1 and a first segment thickness T1, while the second segment has a second segment height H2 and a second segment thickness T2, with the lesser of H1 and H2 defining a minimum segment height Hmin and the lesser of T1 and T2 defining a minimum segment thickness Tmin. The resultant component has a ratio of L:Hmin:Tmin of 20-80:1:0.5-10 where Hmin is between 5 and 500 microns. In specific instances, the nonlinear angle is acute, the multiple segments are rectilinear in cross section, and a segment thickness has an edge resolution of between 0.1 and 2 microns.Type: GrantFiled: August 3, 2009Date of Patent: September 10, 2013Assignee: The Penn State Research FoundationInventors: James H. Adair, Mary Frecker, Christopher Muhlstein, Eric Mockensturm, Harriet Black Nembhard, Randy S. Haluck, Abraham Mathew, Nicholas Antolino, Gregory R Hayes, Milton Aguirre, Rebecca Kirkpatrick, Chumpol Yuangyai
-
Patent number: 8071132Abstract: The present invention provides a method for the synthesis of unagglomerated, highly dispersed, stable core/shell nanocomposite particles comprised of preparing a reverse micelle microemulsion that contains nanocomposite particles, treating the microemulsion with a silane coupling agent, breaking the microemulsion to form a suspension of the nanocomposite particles by adding an acid/alcohol solution to the microemulsion that maintains the suspension of nanocomposite particles at a pH of between about 6 and 7, and simultaneously washing and dispersing the suspension of nanocomposite particles, preferably with a size exclusion HPLC system modified to ensure unagglomeration of the nanocomposite particles. The primary particle size of the nanocomposite particles can range in diameter from between about 1 to 100 nm, preferably from between about 10 to 50 nm, more preferably about 10 to 20 nm, and most preferably about 20 nm.Type: GrantFiled: June 1, 2005Date of Patent: December 6, 2011Assignee: The Penn State Research FoundationInventors: James H. Adair, Sarah M. Rouse, Jun Wang, Mark Kester, Christopher Siedlecki, William B. White, Erwin Vogler, Alan Snyder, Carlo G. Pantano, Victor Ruiz-Velasco, Lawrence Sinoway
-
Publication number: 20110129413Abstract: Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.Type: ApplicationFiled: November 8, 2010Publication date: June 2, 2011Inventors: Thomas T. Morgan, Brian M. Barth, James H. Adair, Rahul Sharma, Mark Kester, Sriram S. Shanmugavelandy, Jill P. Smith, Erhan I. Altinoglu, Gail L. Matters, James M. Kaiser, Christopher McGovern
-
Publication number: 20110046241Abstract: The present invention relates to a method for forming a calcium-based carrier particle consisting of the calcium-based material, an active, with or without a surface modification, a stabilizing agent, and the related composition. The calcium-based particle is illustrated by the general formula Cax(PO4)y(OH)zR and may also include a silica or silica oxide substituent. R is an active or actives such as an organic or inorganic molecule that includes markers, amines, thiols, epoxies, organosilicones, organosilanes, sulfates, and water soluble agents and, as needed, a surface modification, S, which may be either organic or inorganic. A stabilizing agent may be necessary to maintain dispersion of the particles in aqueous media. Examples of a surface modifying material and stabilizing agents are inorganic salts of aluminum and boron or organic materials such as organosilanes or low molecular weight polymers.Type: ApplicationFiled: August 24, 2009Publication date: February 24, 2011Inventors: Timothy S. Keizer, Brett M. Showalter, Bruce A. Keiser, James H. Adair
-
Publication number: 20110046240Abstract: The present invention relates to a method for forming a calcium-based carrier particle consisting of the calcium-based material, an active, with or without a surface modification, a stabilizing agent, and the related composition. The calcium-based particle is illustrated by the general formula Cax(PO4)y(OH)zR and may also include a silica or silica oxide substituent. R is an active or actives such as an organic or inorganic molecule that includes markers, amines, thiols, epoxies, organosilicones, organosilanes, sulfates, and water soluble agents and, as needed, a surface modification, S, which may be either organic or inorganic. A stabilizing agent may be necessary to maintain dispersion of the particles in aqueous media. Examples of a surface modifying material and stabilizing agents are inorganic salts of aluminum and boron or organic materials such as organosilanes or low molecular weight polymers.Type: ApplicationFiled: August 24, 2009Publication date: February 24, 2011Inventors: Timothy S. Keizer, Brett M. Showalter, Bruce A. Keiser, James H. Adair
-
Publication number: 20110046239Abstract: The present invention relates to a method for forming a calcium-based carrier particle consisting of the calcium-based material, an active, with or without a surface modification, a stabilizing agent, and the related composition. The calcium-based particle is illustrated by the general formula Cax(PO4)y(OH)zR and may also include a silica or silica oxide substituent. R is an active or actives such as an organic or inorganic molecule that includes markers, amines, thiols, epoxies, organosilicones, organosilanes, sulfates, and water soluble agents and, as needed, a surface modification, S, which may be either organic or inorganic. A stabilizing agent may be necessary to maintain dispersion of the particles in aqueous media. Examples of a surface modifying material and stabilizing agents are inorganic salts of aluminum and boron or organic materials such as organosilanes or low molecular weight polymers.Type: ApplicationFiled: August 24, 2009Publication date: February 24, 2011Inventors: Bruce A. Keiser, Timothy S. Keizer, Brett M. Showalter, Tiffany Bohnsack, James H. Adair, Mylisa Parette, Amy Knupp, Andrei S. Zelenev, Jason R. Burney
-
Publication number: 20110046238Abstract: The present invention relates to a method for forming a calcium-based carrier particle consisting of the calcium-based material, an active, with or without a surface modification, a stabilizing agent, and the related composition. The calcium-based particle is illustrated by the general formula Cax(PO4)y(OH)zR and may also include a silica or silica oxide substituent. R is an active or actives such as an organic or inorganic molecule that includes markers, amines, thiols, epoxies, organosilicones, organosilanes, sulfates, and water soluble agents and, as needed, a surface modification, S, which may be either organic or inorganic. A stabilizing agent may be necessary to maintain dispersion of the particles in aqueous media. Examples of a surface modifying material and stabilizing agents are inorganic salts of aluminum and boron or organic materials such as organosilanes or low molecular weight polymers.Type: ApplicationFiled: August 24, 2009Publication date: February 24, 2011Inventors: Bruce A. Keiser, Timothy S. Keizer, Brett M. Showalter, Tiffany Bohnsack, James H. Adair, Mylisa Parette, Amy Knupp, Andrei S. Zelenev, Jason R. Burney